Federal Register / Vol. 61, No. 112 / Monday, June 10, 1996 / Notices 29415

TABLE 2.—SHORT-TERM TOXICITY STUDIES SCHEDULED FOR REVIEW BY THE NTP BOARD OF SCIENTIFIC COUNSELORS’

TECHNICAL REPORTS REVIEW SUBCOMMITTEE FROM APRIL 1996 THROUGH 1998—Continued

Chemical name/CAS No. Use Route Species Exposure levels

Short-Term Toxicity Studies Tentatively Scheduled

for Peer Review May 1996:

M-Chloroaniline:

108–42–9 ............................................................. INTR ...... GAV ....... RM ......... R&M 0, 10, 20, 40, 80, 160 43 mg/kg, 20/grp (rats);

10/grp (mice).

O-Chloroaniline:

95–51–2 ............................................................... DYE ....... GAV ....... RM ......... R&M 0, 10, 20, 40, 80, & 160 43 mg/kg, 20/grp

(rats); 10/grp (mice).

Short-Term Toxicity Studies Tentatively Scheduled

for Peer Review June 1996:

AZT+Methadone HCL (AIDS):

Aztmethcomb ....................................................... PHAR ..... GAV ....... MM ......... AZT: 200, 400, or 800 mg/kg/day with Methadone

HCL: 5, 15, or 30 mg/kg/day.

2′, 3′-Dideoxycytidine (AIDS initiative):

7481–89–2 ........................................................... PHAR ..... GAV ....... MM ......... Female mice only: 500, 1000 mg/kg/day.

3, 3′, 4, 4′-Tetrachloroazobenzene:

14047–09–7 ......................................................... HERB ..... GAV ....... RM ......... R&M: 0, 0.1, 1.0, 3.0, 10, or 30 mg/kg body weight

(M&F; 10/group).

1, 1, 2, 2-Tetrachloroethane ....................................... SOLV ..... GAV ....... RM .........

1, 1, 2, 2-Tetrachloroethane:

79–34–5 ............................................................... SOLV ..... MICRO ... RM ......... R&M; R:untreated control, vehicle control, 18, 37,

75, 150, or 300 mg/kg body wt/day; M: untreated

control, vehicle control, 88, 175, 350, 700, or 1400

mg/kg body wt/day; 10/group/sex.

Short-Term Toxicity Studies Tentatively Scheduled

for Peer Review August 1996:

1, 1, 1-Trichloroethane:

71–55–6 ............................................................... SOLV ..... MICRO ... RM ......... R&M: 0, 0.5, 1.0, 2.0, 4.0, 41 and, 8.0% (10/S/S).

Short-Term Toxicity Studies Tentatively Scheduled

for Peer Review December 1996:

CIS & TRANS 1,2-Dichloroethylene:

540–59–0 ............................................................. SOLV ..... MICRO ... RM ......... 55.

CIS-1, 2-Dichloroethylene:

156–59–2 ............................................................. SOLV ..... MICRO ... RM ......... 55.

TRANS-1, 2-Dichloroethylene:

156–60–5 ............................................................. SOLV ..... MICRO ... RM ......... 55.

TRANS-1, 2-Dichloroethylene:

156–60–5 ............................................................. SOLV ..... GAV ....... RM ......... 55.

TRANS-1, 2-Dichloroethylene:

156–60–5 ............................................................. SOLV ..... MICRO ... RM ......... R&M: untreated control, vehicle control, 3125, 6250,

12,500, 25,000, or 50,000 ppm; 10/group/sex.

Abbreviations used: in this report:

Use Primary use category

COMT Contaminates and/or Impurities.

COSM Cosmetics, Perfumes, Fragrances,

Hair Preparations.

DTRG Detergents and Cleaners.

DYE .... As or in Dyes, Inks, and Pigments.

ELEC In Electrical and/or Dielectric Systems.

FOOD Food, Beverages, or Additives.

HERB Herbicide(s).

INTR ... Chemical Intermediate or Catalyst.

PEST Pesticides, General or Unclassified.

PHAR Pharmaceuticals or Intermediates.

PLAS ... As or in Plastics.

PNT ..... Paint Ingredient.

RUBR Rubber Chemical.

SOLV Vehicles and Solvents.

TEXL ... In Manufacture of Textiles.

Route Route of administration

FEED Dosed-Feed.

GAV .... Gavage.

Route Route of administration

INHAL Inhalation.

IP/IJ ..... Intraperitoneal Injection.

IVAG ... Intravaginal.

MICRO Microencapsulation in Feed.

SC&GV Subcutaneous Inj.+Gavage.

SP ....... Topical.

WATER Dosed-Water.

WB ...... Whole Body Exposure.

Spec Species

R .......................... = Rats.

M .......................... = Mice.

[FR Doc. 96–14149 Filed 6–7–96; 8:45 am]

BILLING CODE 4140–01–M

Substance Abuse and Mental Health

Services Administration

Agency Information Collection

Activities: Submission for OMB

Review; Comment Request

Periodically, the Substance Abuse and

Mental Health Services Administration

(SAMHSA) will publish a list of

information collection requests under

OMB review, in compliance with the

Paperwork Reduction Act (44 U.S.C.

Chapter 35). To request a copy of these

documents, call the SAMHSA Reports

Clearance Officer on (301) 443–0525.

FY 1997/1998 Substance Abuse

Prevention and Treatment Block Grant

Application Format—Revision of a

currently approved collection—The

Public Health Service Act (42 U.S.C.

300x 1–9) authorizes block grants to

States for the purpose of providing

prevention and treatment services.
29416 Federal Register / Vol. 61, No. 112 / Monday, June 10, 1996 / Notices

Under the provisions of the law, States

may receive allotments only after an

application is approved by the

Secretary, DHHS. The uniform

application format provides States with

the forms and instructions for their

applications so they can comply with

the requirements of the law and

regulations implementing the law. The

annual burden estimate is shown below:

No. of

respondents

No. of responses per

respondent

Avg. burden per

response

Total

annual

burden

60 1 561.5

hours.

33,690

hours.

Written comments and

recommendations concerning the

proposed information collection should

be sent within 30 days of this notice to:

Virginia Huth, Human Resources and

Housing Branch, Office of Management

and Budget, New Executive Office

Building, Room 10236, Washington, DC

20503.

Dated: May 31, 1996.

Patricia S. Bransford,

Acting Executive Officer, Substance Abuse

and Mental Health Services Administration.

[FR Doc. 96–14573 Filed 6–7–96; 8:45 am]

BILLING CODE 4162–20–P

Food and Drug Administration

Import and Private Laboratory

Communities: Public Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice of public meetings.

SUMMARY: The Food and Drug

Administration’s (FDA’s) Office of

Regulatory Affairs (ORA) is announcing

a series of Grassroots Meetings to be

held with the import and private

laboratory communities. These meetings

will follow a prescribed format similar

to what was used recently in the

Grassroots Regulatory Partnership

Meetings held as part of the National

Performance Review and will be

conducted by key agency officials

including ORA’s Division of Field

Science, the Division of Import

Operations and Policy, and other

representatives from the field and

headquarters.

The purpose of the meetings is to

establish a dialogue with the import,

domestic, and private laboratory

communities, trade associations, and

other interested persons. The intent of

the dialogue is to explore ways the

agency might improve current policy

and procedures related to the use of

private laboratories to establish product

compliance with FDA regulations. After

the meetings a report will be prepared

outlining a strategy for making positive

changes in policy and/or procedures

related to the agency’s use of analytical

data from private laboratories.

DATES: The public meetings are

scheduled as follows:

1. Tuesday, June 25, 1996, 9 a.m. to

4:30 p.m., Brooklyn, NY.

2. Friday, June 28, 1996, 9 a.m. to 4:30

p.m., Orlando, FL.

3. Tuesday, July 9, 1996, 9 a.m. to 4:30

p.m., Houston, TX.

4. Thursday, July 11, 1996, 9 a.m. to

4:30 p.m., Oakland, CA.

ADDRESSES: The public meetings will be

held at the following locations:

1. Brooklyn—Fort Hamilton Community

Club, 101st St. and Fort Hamilton

Pkwy., Bldg. 207, Brooklyn, NY.

2. Orlando—Sheraton Plaza Hotel, 1500

Sand Lake Rd., Orlando, FL.

3. Houston—Houston Plaza Hilton, 6633

Travis St., Houston, TX.

4. Oakland—Oakland Federal Bldg.,

Edward Royball Auditorium, 1301 Clay

St., Oakland, CA.

FOR FURTHER INFORMATION CONTACT:

Regarding attendance at the Brooklyn,

NY public meeting: George Walden,

Small Business Representative

Northeast Region, 850 Third Ave.,

Brooklyn, NY 11232, 718–965–

5300, ext. 5528 or FAX 718–965–

5759.

Regarding attendance at the Orlando,

FL public meeting: Barbara WardGroves, Small Business

Representative Southeast Region, 60

Eighth St. NE., Atlanta, GA 30309,

404–347–4001, ext. 5256 or FAX

404–347–4349.

Regarding attendance at the Houston,

TX public meeting: Marie T.

Falcone, Small Business

Representative Southwest Region,

7920 Elmbrook Dr., suite 102,

Dallas, TX 75247–4982, 214–655–

8100, ext. 128 or FAX 214–655–

8130.

Regarding attendance at the Oakland,

CA public meeting: Mark S. Roh,

Small Business Representative

Pacific Region, Oakland Federal

Bldg., 1301 Clay St., suite 1180–N,

Oakland, CA 94612–5217, 510–

637–3980 or FAX 510–637–3977.

In addition to this public notice of the

meetings, invitations will be sent

directly to interested persons

representing private laboratories,

importers, brokers, independent

samplers, scientific and trade

associations, accreditation bodies, and

domestic users of private laboratories.

Interested persons who have not

received an invitation to attend one of

these meetings by June 7, 1996, may

contact the Small Business

Representatives specified above for

registration forms.

Persons who are unable to attend, or

who cannot be accommodated due to

space limitations are invited to provide

written comments. Written comments

may be submitted to Liza Lehman,

Division of Field Science (HFC–140),

5600 Fishers Lane, rm. 12–41, Rockville,

MD 20857. Issues submitted in writing

will be included for discussion at the

meetings and will appear in the final

report.

Questions related to these meetings

should be directed to Richard A.

Baldwin or Liza Lehman (address

above) or by calling 301–443–7103

between 8 a.m. and 4:30 p.m.

SUPPLEMENTARY INFORMATION: The

following background information is

provided for meeting participants. The

term ‘‘private laboratory’’ refers to those

private sector laboratories that conduct

analysis on freely marketed, FDA

regulated products whose analytical

data is submitted to the agency in order

to demonstrate a product’s compliance

with laws and regulations administered

by FDA.

Meeting Objectives

(1) To establish a dialogue with the

import, domestic, and private laboratory

communities; trade associations; and

other interested persons on ways the

agency might improve current policy

and procedures related to the use of

private laboratories to establish product

compliance with FDA laws and

regulations.

(2) To obtain information and views

from interested persons on ways the

agency might enhance its use of private

laboratories to facilitate getting products

that comply with applicable laws and

regulations to the consumer while

removing non-compliant products from

the marketplace.

The following workshops will be

offered at each meeting:

Workshop I

Workshop I will focus on the

following issues:

(1) What practices, procedures, or

policies should be changed so that

private sector testing expedites the

removal of products that do not comply

with FDA laws and regulations and the

distribution of products that are fully

compliant?

(2) What is FDA’s experience with

how the current process works?

(3) What needs to be changed about

the current process?

(4) Why and how?